🟢 AIM ImmunoTech is trading 7.29% up in pre-market after European Long COVID patent protection through 2041

AIM ImmunoTech is trading 7.29% up at $0.25 in pre-market after announcing European and United Kingdom patent protection for Ampligen’s Long COVID treatment through June 2041.

• The September 2, 2026 announcement significantly expands coverage across major European markets and supports longer-term commercial exclusivity.
• The move is company-specific rather than broad-market driven; no additional major overnight announcement was identified.
• Pre-market volume and activity details were unavailable.